Abstract: A cognitive training method has a step of obtaining sensor data of a subject during a memory exercise which in turn determines whether the sensor data includes predetermined information indicative of cognitive functions used for remembering. The step of advancing the memory exercise is carried out when it is determined that the sensor data includes predetermined information indicative of cognitive functions used for remembering. The step of calculating an objective cognitive assessment of the subject is carried out when the memory exercise is completed and cognitive training is measured at least partially in response to the advancing of the memory exercise. The fact that an objective cognitive assessment is calculated provides a method of using an autodidactic cognitive training device.

Abstract: A method for dynamically optimized course of learning is provided. The method comprises creating a learning environment profile of target leaners of a target course, wherein the learning environment profile comprises one or more sets of data collected from the target leaners and one or more teachers of the target course; establishing a plurality of parameters for optimizing cerebral learning for the target leaners in response to the one or more sets of data; optimizing the course of learning in accordance with the plurality of parameters; presenting the optimized course of learning to one or more of the target learners; measuring the cerebral learning of the one or more target leaners of the optimized course or learning to arrive at an effectiveness feedback (EFK) of the plurality of parameters; and refining one or more of the plurality of parameters to dynamically optimize the course of learning when the effectiveness feedback falls below a predetermined threshold. Associated system is also provided.

Abstract: A device and method for generating a representation of a subject's attention level. The device measures brain signals from the subject; extracts temporal features from the brain signals; classifies the extracted temporal features using a classifier to give a score X1; extracts spectral-spatial features from the brain signals; selects spectral-spatial features containing discriminative information between concentration and non-concentration states from the set of extracted spectral-spatial features; classifies the selected spectral-spatial features using a classifier to give a score X2; combines the scores X1 and X2 to give a single score; and presents the score to the subject.

Abstract: A cognitive training method has a step of obtaining sensor data of a subject during a memory exercise which in turns determining whether the sensor data includes predetermined information indicative of cognitive functions used for remembering. The step of advancing the memory exercise is carried out when it is determined that the sensor data includes predetermined information indicative of cognitive functions used for remembering. The step of calculating an objective cognitive assessment of the subject when the memory exercise is completed and a cognitive training is measured at least partially in response to the advancing the memory exercise. The fact that an objective cognitive assessment is calculated provides a method of using an autodidactic cognitive training device.

Abstract: According to one aspect, there is provided a method for assessing the treatment of attention-deficit/hyperactivity disorder (ADHD) in a subject, the method comprising: obtaining electroencephalographic (EEG) data relating to a plurality of subjects diagnosed with ADHD; extracting, for each of the plurality of subjects, at least one feature from the EEG data relating to that subject; formulating a prediction model by performing regression analysis to map the extracted features against one or more markers for each of the plurality of subjects; and determining that the prediction model provides an ADHD assessment if one or more of the markers are indicators of a clinical measure of interest.

Abstract: A device and method for generating a representation of a subject's attention level. The device comprises means for measuring brain signals from the subject; means for extracting temporal features from the brain signals; means for classifying the extracted temporal features using a classifier to give a score x1; means for extracting spectral-spatial features from the brain signals; means for selecting spectral-spatial features containing discriminative information between concentration and non-concentration states from the set of extracted spectral-spatial features; means for classifying the selected spectral-spatial features using a classifier to give a score x2; means for combining the scores x1 and x2 to give a single score; and means for presenting said score to the subject.

Abstract: Methods and compositions are provided for treating vascular depression. The methods involve administering to a subject in need thereof a xanthine derivative in a therapeutically effective amount to treat vascular depression, particularly the xanthine derivatives pentoxifylline or propentofylline. The methods may further include administration of an additional therapeutic agent in combination with the xanthine derivative selected from the group consisting of a selective serotonin reuptake inhibitor (SSRI), a serotonin-norepinephrine reuptake inhibitor (SNRI), and a drug used in the treatment of cerebrovascular disease. Compositions of the invention include pharmaceutical compositions and kits for treating vascular depression in a subject in need thereof that include therapeutically effective amounts of a xanthine derivative and an additional therapeutic agent selected from the group consisting of an SSRI, an SNRI, and a drug used in the treatment of cerebrovascular disease.

Abstract: Methods and compositions are provided for treating dermatological diseases, disorders, and pathologies, including seborrheic dermatitis, in a subject in need thereof. In some embodiments, methods are provided for the treatment of a dermatological disease, disorder, or pathology comprising, topically administering to a subject in need of dermatological treatment a composition comprising a therapeutically effective amount of bupropion, lithium or lithium salicylate, or combinations thereof.

Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant.

Abstract: The present embodiments relate to methods for the treatment of Rett Syndrome. More specifically, the present embodiments relate to pivagabine for use in the treatment of Rett Syndrome. Some embodiments relate to treatment of a patient with Rett Syndrome. Other embodiments relate to treatment of the indications of Rett Syndrome.

Abstract: Methods and compositions are provided for treating vascular depression. The methods involve administering to a subject in need thereof a xanthine derivative in a therapeutically effective amount to treat vascular depression, particularly the xanthine derivatives pentoxifylline or propentofylline. The methods may further include administration of an additional therapeutic agent in combination with the xanthine derivative selected from the group consisting of a selective serotonin reuptake inhibitor (SSRI), a serotonin-norepinephrine reuptake inhibitor (SNRI), and a drug used in the treatment of cerebrovascular disease. Compositions of the invention include pharmaceutical compositions and kits for treating vascular depression in a subject in need thereof that include therapeutically effective amounts of a xanthine derivative and an additional therapeutic agent selected from the group consisting of an SSRI, an SNRI, and a drug used in the treatment of cerebrovascular disease.

Abstract: A method of treating a subject for a serotonergic neurotransmission dysregulation disorder, comprises administering the subject a serotonin enhancer (e.g., a serotonin reuptake inhibitor) in an amount effective to treat the disorder; and concurrently administering the subject 5-hydroxytryptophan in an amount effective to enhance the activity of the serotonin enahancer, (e.g., serotonin reuptake inhibitor). In preferred embodiments the disorder is depression, anxiety, or substance abuse.

Abstract: A method of screening a subject for a serotonergic neurotransmission dysregulation disorder comprises detecting the presence or absence of an Tph2 mutation in the subject; and then determining that the subject is at increased risk of a serotonergic neurotransmission dysregulation disorder due to the presence or absence of the Tph2 mutation.

Abstract: The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.

Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an antidiabetic and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with an antidiabetic and an anticonvulsant.

Abstract: The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.

Abstract: The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.

Abstract: The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.

Abstract: Selective serotonin reuptake inhibitors useful in the treatment of non-cardiac chest pain or the treatment of symptoms of gastro-esophageal reflux disease.